يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"MTOR Inhibitors"', وقت الاستعلام: 0.83s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Recent advances and limitations of mTOR inhibitors in the treatment of cancer.

    المؤلفون: Ali, Eunus S.1,2,3 (AUTHOR), Mitra, Kangkana4 (AUTHOR), Akter, Shamima5 (AUTHOR), Ramproshad, Sarker6 (AUTHOR), Mondal, Banani6 (AUTHOR), Khan, Ishaq N.7 (AUTHOR), Islam, Muhammad Torequl8 (AUTHOR), Sharifi-Rad, Javad9 (AUTHOR) javad.sharifirad@gmail.com, Calina, Daniela10 (AUTHOR) calinadaniela@gmail.com, Cho, William C.11 (AUTHOR) chocs@ha.org.hk

    المصدر: Cancer Cell International. 9/15/2022, Vol. 22 Issue 1, p1-16. 16p.

    مصطلحات موضوعية: *RAPAMYCIN, *MTOR inhibitors, *IMMUNOSUPPRESSIVE agents, *CELL transformation, *CANCER treatment, *CELL proliferation

    النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    The ginsenoside Rk3 exerts anti-esophageal cancer activity in vitro and in vivo by mediating apoptosis and autophagy through regulation of the PI3K/Akt/mTOR pathway.

    المؤلفون: Liu, Huanhuan, Zhao, Jiaqi, Fu, Rongzhan, Zhu, Chenhui, Fan, Daidi

    المصدر: PLoS ONE; 5/15/2019, Vol. 14 Issue 5, p1-16, 16p

    مصطلحات موضوعية: AUTOPHAGY, GINSENG, ESOPHAGEAL cancer, MTOR inhibitors, CELL proliferation, ANTINEOPLASTIC agents

    النص الكامل

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.

    المؤلفون: Mensah, Felix A, Blaize, Jean-Pierre, Bryan, Locke J

    المصدر: OncoTargets & Therapy; Aug2018, Vol. 11, p4817-4827, 11p

    مصطلحات موضوعية: PHOSPHATIDYLINOSITOL 3-kinases, CELL proliferation, CANCER treatment, MTOR inhibitors, ESTRONE

    النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

    المؤلفون: Di Leo, Angelo1 angelo.dileo@uslcentro.toscana.it, Johnston, Stephen2, Lee, Keun Seok3, Ciruelos, Eva4, Lønning, Per E5,6, Janni, Wolfgang7, O'Regan, Ruth8, Mouret-Reynier, Marie-Ange9, Kalev, Dimitar10, Egle, Daniel11, Csőszi, Tibor12, Bordonaro, Roberto13, Decker, Thomas14, Tjan-Heijnen, Vivianne C G15, Blau, Sibel16, Schirone, Alessio17, Weber, Denis18, El-Hashimy, Mona19, Dharan, Bharani19, Sellami, Dalila19

    المصدر: Lancet Oncology. Jan2018, Vol. 19 Issue 1, p87-100. 14p.

    مصطلحات موضوعية: *HORMONE receptor positive breast cancer, *BREAST cancer patients, *HER2 gene, *MTOR inhibitors, *CELL growth, *CELL proliferation, *CANCER treatment, *PROTEIN analysis, *AMINOPYRIDINES, *ANTINEOPLASTIC agents, *BREAST tumors, *CELL receptors, *COMPARATIVE studies, *ESTRADIOL, *ESTROGEN antagonists, *HETEROCYCLIC compounds, *RESEARCH methodology, *MEDICAL cooperation, *PHOSPHOTRANSFERASES, *PROGNOSIS, *RESEARCH, *TIME, *EVALUATION research, *TREATMENT effectiveness, *BLIND experiment, *DISEASE progression, *PROTEIN kinase inhibitors, *CHEMICAL inhibitors


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث